377 related articles for article (PubMed ID: 16637459)
1. Emerging anticoagulants: mechanism of action and future potential.
Klement P; Rak J
Vnitr Lek; 2006 Mar; 52 Suppl 1():119-22. PubMed ID: 16637459
[TBL] [Abstract][Full Text] [Related]
2. Comparative Anticoagulant and Thrombin Generation Inhibitory Profile of Heparin, Sulodexide and Its Components.
Siddiqui F; Hoppensteadt D; Bontekoe E; Farooqui A; Jeske W; Fareed J
Clin Appl Thromb Hemost; 2020; 26():1076029620954913. PubMed ID: 33030036
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of propagation of coagulation: factors V and X.
Toschi V; Lettino M
Br J Clin Pharmacol; 2011 Oct; 72(4):563-80. PubMed ID: 21545479
[TBL] [Abstract][Full Text] [Related]
4. [New anticoagulants in 2024: Development of factor XI and XIa inhibitors].
Bentounes NK; Melicine S; Martin AC; Smadja DM; Gendron N
Ann Biol Clin (Paris); 2024 Apr; 82(1):9-23. PubMed ID: 38638015
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications.
Alquwaizani M; Buckley L; Adams C; Fanikos J
Curr Emerg Hosp Med Rep; 2013 Jun; 1(2):83-97. PubMed ID: 23687625
[TBL] [Abstract][Full Text] [Related]
6. Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies.
Luan D; Zai M; Varner JD
PLoS Comput Biol; 2007 Jul; 3(7):e142. PubMed ID: 17658944
[TBL] [Abstract][Full Text] [Related]
7. Changes in Internal Structure and Dynamics upon Binding Stabilise the Nematode Anticoagulant NAPc2.
Woodward E; Duggan BM
Biomolecules; 2024 Mar; 14(4):. PubMed ID: 38672438
[TBL] [Abstract][Full Text] [Related]
8. Single-domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors.
Barbon E; Ayme G; Mohamadi A; Ottavi JF; Kawecki C; Casari C; Verhenne S; Marmier S; van Wittenberghe L; Charles S; Collaud F; Denis CV; Christophe OD; Mingozzi F; Lenting PJ
EMBO Mol Med; 2020 Apr; 12(4):e11298. PubMed ID: 32159286
[TBL] [Abstract][Full Text] [Related]
9. Antithrombotics and new interventions for venous thromboembolism: Exploring possibilities beyond factor IIa and factor Xa inhibition.
Mavromanoli AC; Barco S; Konstantinides SV
Res Pract Thromb Haemost; 2021 May; 5(4):. PubMed ID: 34027284
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis.
Goel A; Tathireddy H; Wang SH; Vu HH; Puy C; Hinds MT; Zonies D; McCarty OJT; Shatzel JJ
Semin Thromb Hemost; 2023 Apr; ():. PubMed ID: 37044117
[TBL] [Abstract][Full Text] [Related]
11. Development of supramolecular anticoagulants with on-demand reversibility.
Dockerill M; Ford DJ; Angerani S; Alwis I; Dowman LJ; Ripoll-Rozada J; Smythe RE; Liu JST; Pereira PJB; Jackson SP; Payne RJ; Winssinger N
Nat Biotechnol; 2024 Apr; ():. PubMed ID: 38689027
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan).
Yamashita T; Koretsune Y; Nagao T; Shiosakai K
J Arrhythm; 2021 Apr; 37(2):370-383. PubMed ID: 33850579
[TBL] [Abstract][Full Text] [Related]
13. Direct Oral Anticoagulant Use in Special Populations: Elderly, Obesity, and Renal Failure.
White EM; Coons JC
Curr Cardiol Rep; 2021 Mar; 23(4):27. PubMed ID: 33655373
[TBL] [Abstract][Full Text] [Related]
14. Retrospective Review of Prescribing Patterns in Cancer-Associated Thrombosis: A Single Center Experience in Edmonton, Alberta, Canada.
Kaliel H; Mior M; Quan S; Ghosh S; Wu C; Bungard TJ
Clin Appl Thromb Hemost; 2021; 27():1076029620975489. PubMed ID: 33443455
[TBL] [Abstract][Full Text] [Related]
15. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
Mainbourg S; Cucherat M; Provencher S; Bertoletti L; Nony P; Gueyffier F; Mismetti P; Grange C; Durieu I; Kilo R; Laporte S; Grenet G; Lega JC;
Thromb Res; 2021 Jan; 197():24-32. PubMed ID: 33161284
[TBL] [Abstract][Full Text] [Related]
16. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Runner RP; Gottschalk MB; Staley CA; Pour AE; Roberson JR
J Arthroplasty; 2019 Apr; 34(4):729-734. PubMed ID: 30685257
[TBL] [Abstract][Full Text] [Related]
17. Early, real-world experience with direct oral anticoagulants in the treatment of intermediate-high risk acute pulmonary embolism.
Santos SM; Cunha S; Baptista R; Monteiro S; Monteiro P; Gonçalves F; Pêgo M
Rev Port Cardiol; 2017 Nov; 36(11):801-806. PubMed ID: 29126891
[TBL] [Abstract][Full Text] [Related]
18. Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration.
Yanagisawa S; Inden Y; Fujii A; Ando M; Funabiki J; Murase Y; Takenaka M; Otake N; Ikai Y; Sakamoto Y; Shibata R; Murohara T
Heart Rhythm; 2018 Mar; 15(3):348-354. PubMed ID: 29107192
[TBL] [Abstract][Full Text] [Related]
19. A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score.
Hijazi Z; Oldgren J; Lindbäck J; Alexander JH; Connolly SJ; Eikelboom JW; Ezekowitz MD; Held C; Hylek EM; Lopes RD; Yusuf S; Granger CB; Siegbahn A; Wallentin L;
Eur Heart J; 2018 Feb; 39(6):477-485. PubMed ID: 29069359
[TBL] [Abstract][Full Text] [Related]
20. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
De Caterina R; Andersson U; Alexander JH; Al-Khatib SM; Bahit MC; Goto S; Hanna M; Held C; Hohnloser S; Hylek EM; Lanas F; Lopes RD; López-Sendón J; Renda G; Horowitz J; Granger CB; Wallentin L;
Am Heart J; 2016 May; 175():175-83. PubMed ID: 27179738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
